Financings Of The Fortnight Checks The Corporate Venture Numbers
This article was originally published in The Pink Sheet Daily
Executive Summary
Corporate venture investment is seen as increasingly important in life sciences finance. Plus news on recent financings by Retrophin, Sophiris Bio, Regado Biosciences and Tigercat Pharma.
You may also be interested in...
Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.
Hospitals, Insurers Enjoy Growing Influence As VCs
Over a decade ago, hospital companies began establishing venture capital funds to ride shotgun with institutional VCs, hoping to get a glimpse of health care’s future. Today, under health care reform, VC groups sponsored by providers and payors increasingly find themselves in the driver’s seat, looking for the start-ups that might have solutions to the industry’s biggest problem – cost.
Device Start-Ups Reap More Corporate Venture
Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.